Insider Buying: Conexeu Sciences (NASDAQ:CNXU) Director Purchases $499,998.00 in Stock

Key Points

• Director Lynn Sebastian Purcell purchased 166,666 CNXU shares at $3.00 each, investing approximately $499,998 and increasing direct ownership by 5.65% to 3.12 million shares.
• Conexeu Sciences shares rose 8.5% to $3.32, but remain near their 52-week low of $3.05 and well below the 52-week high of $18.79. The company reported a quarterly loss of $0.29 per share, missing the $0.10 loss consensus estimate.
• Analyst views are mixed—one Buy, one Hold, and one Sell—with an overall consensus rating of Hold and a $20.00 target price.

Conexeu Sciences Inc. (NASDAQ:CNXU - Get Free Report) Director Lynn Sebastian Purcell acquired 166,666 shares of Conexeu Sciences stock in a transaction that occurred on Thursday, October 15th. The stock was bought at an average price of $3.00 per share, with a total value of $499,998.00. Following the purchase, the director directly owned 3,118,514 shares of the company's stock, valued at approximately $9,355,542. This trade represents a 5.65% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Conexeu Sciences Trading Up 8.5%

CNXU stock traded up $0.26 during trading on Monday, reaching $3.32. 365,524 shares of the company were exchanged, compared to its average volume of 192,955. The firm's 50 day moving average is $5.45. The stock has a market cap of $93.66 million and a P/E ratio of -8.30. Conexeu Sciences Inc. has a 52-week low of $3.05 and a 52-week high of $18.79.

Conexeu Sciences (NASDAQ:CNXU - Get Free Report) last released its quarterly earnings results on Monday, September 14th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.19). Equities analysts expect that Conexeu Sciences Inc. will post -0.40 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CNXU has been the subject of several research reports. HC Wainwright initiated coverage on Conexeu Sciences in a research note on Monday, June 22nd. They set a "buy" rating and a $20.00 price target for the company. Zacks Research raised shares of Conexeu Sciences to a "hold" rating in a research note on Monday, June 29th. Finally, Weiss Ratings started coverage on shares of Conexeu Sciences in a research report on Monday, August 17th. They set a "sell (e-)" rating for the company. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $20.00.

About Conexeu Sciences

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. --- Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property ("IP") developed over more than a decade at the University of British Columbia (the "University") and the BC Professional Firefighters Burn and Wound Healing Laboratory.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.